STAA Stock Analysis
ST
Neutral
Based on Eyestock quantitative analysis, STAA`s fundamental data and valuation indicate an investment grade of Neutral at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly undervalued
STAAR Surgical Co. engages in the development, manufacture, production, marketing, and sale of implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company is headquartered in Monrovia California, California and currently employs 882 full-time employees. The company is a manufacturer of lenses used worldwide in corrective or refractive surgery. The company sells its products in approximately 75 countries, with direct distribution in Japan, Germany, Spain, the United States, Canada, the United Kingdom, and Singapore, with a combination of direct distribution and independent distribution in China, Korea, India, France, Benelux, and Italy. Its manufacturing facility in Monrovia, California, makes the Visian implantable Collamer lens product family, including the EVO Visian ICL, preloaded silicone cataract intraocular lenses and injector systems. Its manufacturing facility in Brugg, Switzerland, operates an administrative, distribution and operational through its subsidiary, STAAR Surgical AG. The company operates administrative and distribution facilities in Japan through its subsidiary, STAAR Japan Inc.